Psychotherapy for Joint Pain in Breast Cancer Survivors
Trial Summary
What is the purpose of this trial?
The researchers are doing this study to compare two different types of group therapy and find out whether they are effective approaches for helping breast cancer survivors manage joint pain caused by aromatase inhibitors (AI). This type of joint pain is called AI-associated arthralgia, or AIA, and it is common in people taking AIs. AIA and its associated symptoms can make some people decide to stop taking their medication. The study will look at the effects of two different types of group therapy on participants' cancer-related symptoms (such as pain, fatigue, and anxiety), their ability to continue taking AIs on a regular schedule, and their quality of life. We will measure participants' quality of life by having them fill out questionnaires. Both groups will have 2-hour group therapy sessions once a week, over the course of 8 weeks. During the sessions, you will be in a group of 6-10 participants, who may be a mixture of patients from both MSK and University of California San Diego (UCSD).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does require that you continue taking aromatase inhibitors (AIs) for at least another 12 months.
What data supports the effectiveness of the treatment Supportive Psychotherapy With MORE Interventions for joint pain in breast cancer survivors?
Research shows that mindfulness-based interventions, like those used in Mindfulness-Oriented Recovery Enhancement (MORE), can help reduce persistent pain in women treated for breast cancer. This suggests that incorporating MORE into supportive psychotherapy might be effective for managing joint pain in breast cancer survivors.12345
Is psychotherapy safe for breast cancer survivors?
How does the treatment Supportive Psychotherapy With MORE Interventions differ from other treatments for joint pain in breast cancer survivors?
This treatment is unique because it combines supportive psychotherapy with Mindfulness-Oriented Recovery Enhancement (MORE) interventions, which focus on mindfulness and cognitive techniques to help manage pain and improve psychological well-being, unlike traditional treatments that may focus solely on physical therapy or medication.3461011
Research Team
Jun Mao, MD, MSCE
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for English-speaking women over 18 with a history of stage I-III breast cancer, currently free of cancer and taking third-generation AI therapy for at least 28 days. They must have significant joint pain attributed to their medication and be willing to attend video-call therapy sessions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in either Supportive Psychotherapy or MORE Treatment, consisting of eight weekly two-hour group sessions.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at weeks 12 and 24.
Treatment Details
Interventions
- Supportive Psychotherapy With MORE Interventions
- Supportive Psychotherapy Without MORE Interventions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
National Institutes of Health (NIH)
Collaborator